UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2287-6
Program Prior Authorization/Medical Necessity
Medication Zoryve® (roflumilast)
P&T Approval Date 9/2022, 2/2023, 11/2023, 2/2024, 12/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Zoryve (roflumilast) 0.3% cream is a phosphodiesterase 4 inhibitor indicated for topical treatment
of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older. Zoryve
(roflumilast) foam is indicated for the treatment of seborrheic dermatitis in adult and pediatric
patients 9 years of age and older. Zoryve (roflumilast) 0.15% cream is indicated for the topical
treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and
older.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Zoryve 0.3% cream will be approved based on all of the following criteria:
(1) Diagnosis of plaque psoriasis
-AND-
(2) Minimum duration of a 4-week trial and failure, contraindication, or intolerance
to one of the following topical therapies:
(a) Corticosteroids (e.g., betamethasone, clobetasol, desonide)
(b) Vitamin D analogs (e.g., calcitriol, calcipotriene)
(c) Tazarotene
(d) Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
(e) Anthralin
(f) Coal tar
-AND-
(3) Patient is not receiving Zoryve 0.3% cream in combination with a Targeted
Immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
2. Reauthorization
a. Zoryve 0.3% cream will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to therapy
-AND-
(2) Patient is not receiving Zoryve 0.3% cream in combination with a Targeted
Immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
B. Seborrheic Dermatitis
1. Initial Authorization
a. Zoryve foam will be approved based upon the following criterion:
(1) Diagnosis of seborrheic dermatitis
-AND-
(2) Minimum duration of a 4-week trial and failure, contraindication, or intolerance
to at least one of the following therapies:
(a) Topical corticosteroids (e.g., betamethasone, hydrocortisone)
(b) Topical, shampoo, or systemic antifungals (e.g., ketoconazole, ciclopirox,
itraconazole)
(c) Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
-AND-
(3) Patient is not receiving Zoryve foam in combination with either of the following:
(a) Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry
(tralokinumab-ldrm)]
(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),
Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
© 2025 UnitedHealthcare Services, Inc.
2
a. Zoryve foam will be approved based upon the following criterion:
(1) Documentation of positive clinical response to therapy
-AND-
(2) Patient is not receiving Zoryve foam in combination with either of the
following:
(a) Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry
(tralokinumab-ldrm)]
(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),
Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]
Authorization will be issued for 12 months.
C. Atopic Dermatitis
1. Initial Authorization
a. Zoryve 0.15% cream will be approved based on all of the following criteria:
(1) Diagnosis of mild to moderate atopic dermatitis
-AND-
(2) History of failure, contraindication, or intolerance to one of the following
therapeutic classes of topical therapies:
(a) One of the following:
For mild atopic dermatitis: a topical corticosteroid [e.g., DesOwen
o
(desonide), hydrocortisone] (any potency)
For moderate atopic dermatitis: a topical corticosteroid of at least a
o
medium- to high-potency (e.g., Elocon (mometasone furoate),
Synalar (fluocinolone acetonide), Lidex (fluocinonide)]
(b) One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic
(tacrolimus)]*
-AND-
(3) Patient is not receiving Zoryve 0.15% cream in combination with a targeted
immunomodulator [e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib),
Dupixent (dupilumab), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Zoryve 0.15% cream will be approved based on both of the following criteria:
© 2025 UnitedHealthcare Services, Inc.
3
(1) Documentation of positive clinical response to therapy
-AND-
(2) Patient is not receiving Zoryve 0.15% cream in combination with a targeted
immunomodulator [e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib),
Dupixent (dupilumab), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
* Elidel and Protopic/tacrolimus ointment require prior authorization.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Zoryve cream [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; October
2023.
2. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the
management and treatment of psoriasis with topical therapy and alternative medicine modalities
for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70.
3. Zoryve foam [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; December
2023.
Program Prior Authorization/Medical Necessity - Zoryve (tapinarof)
Change Control
9/2022 New program.
2/2023 Revised trial and failure requirement from either two topical therapies
or calcipotriene and betamethasone dipropionate to a trial and failure of
one topical therapy.
11/2023 Updated not to be used in combination to Targeted Immunomodulators.
Simplified reauthorization criteria to only require positive clinical
response and not used in combination with other treatment medications.
Updated background to include patients 6 years of age and older.
Updated reference.
2/2024 Added criteria for Zoryve foam for seborrheic dermatitis. Updated
background and reference.
12/2024 Added criteria for Zoryve 0.15% cream for atopic dermatitis. Updated
plaque psoriasis criteria to specify 0.3% cream. Updated all
© 2025 UnitedHealthcare Services, Inc.
4
authorizations to 12 months. Removed prescriber requirements.
Updated background and reference.
2/2025 Updated step therapy requirements for atopic dermatitis to one agent
and removed Eucrisa as a required step agent. Updated prior
authorization footnote.
© 2025 UnitedHealthcare Services, Inc.
5